| CARLAT PUBLISHING

Research tells us how to start meds, but rarely when to stop them. This study brings some needed answers on discontinuing antipsychotics after recovery from psychotic depression. Read More

Nuedexta in Agitated Dementia

Nuedexta is indicated for pseudobulbar affect, but when the manufacturer attempted to expand its use into agitation in dementia they ran into some heavy legal penalties. Here we take a closer look at the published and unpublished trials to see what ─ if anything ─ is salvageable. We’ll also show you how to prescribe this high-cost drug as a generic equivalent. Read More

Andrew Miller, Vice Chair of Psychiatry Research at Emory University, translates two decades research on inflammation and depression into practical terms, including a low-cost biomarker that may guide antidepressant selection. Read More

Pramipexole is a selective agonist at the dopamine D3 receptor, which is thought to regulate hedonic drive. It is FDA approved in Parkinson’s disease and restless legs syndrome, and has five randomized controlled trials in depression. Read More

Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)
Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
READ MORE

General Psychiatry
Using SAMe In Clinical Practice with Garrett Rossi, MD
Read More

General Psychiatry
Psychopharm Commandment #6: MAOIs
MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.
Listen now